ARTICLE | Company News
Amgen, Sanofi, U.S. Department of Health and Human Services other news
October 17, 2016 7:00 AM UTC
HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Amgen and Sanofi’s Genzyme Corp. unit separate contracts for two products to treat injuries to bone marrow in radiological or nuclear incidents. BARDA will purchase Neulasta pegfilgrastim, a pegylated G-CSF, from Amgen for $37.7 million. Neulasta is approved to treat high radiation levels that damage bone marrow. ...